| Bankruptcy/Liquidation | Company files for bankruptcy protection or initiates formal liquidation proceedings | 8-K (1.03), 15-12B |
| C-Level Change | CEO, CFO, COO, or other named executive officer departs, is appointed, or changes role | 8-K (5.02) |
| Corporate Earnings | Quarterly or annual earnings release, including revenue, EPS, and guidance | 8-K (2.02), 10-Q, 10-K |
| Credit Ratings | Credit rating upgrade, downgrade, placement on watch, or outlook change by a ratings agency | 8-K (8.01) |
| Deal Termination | A previously announced merger, acquisition, partnership, or deal is formally cancelled | 8-K (1.02) |
| Delisting | Company receives a delisting notice or non-compliance warning from a stock exchange | 8-K (3.01) |
| Dividends | Dividend declaration, increase, reduction, suspension, or special dividend announced | 8-K (8.01) |
| Drug Trial/Clinical Data | Clinical trial results, interim data readouts, or phase completion disclosures | 8-K (8.01) |
| Drug Updates | FDA submission, new drug application (NDA), biologics license application (BLA), or pipeline update | 8-K (8.01) |
| Earnings Revision Guidance | Company revises previously issued earnings or revenue guidance — upward or downward | 8-K (7.01) |
| Equity/Debt Offerings | New share issuance, secondary offering, convertible note, or bond offering announced or priced | 8-K (1.01), S-1, S-3 |
| ESG | Environmental, social, or governance disclosures, commitments, or incidents | Various |
| FDA Approval/Rejections | FDA grants approval for a drug or medical device, or issues a complete response letter (CRL) | 8-K (8.01) |
| Geopolitics/Market News | Macro-level geopolitical or market events that directly impact the company’s operations or outlook | 8-K (8.01) |
| IPO News | IPO pricing, S-1 filing, listing date announcement, or post-IPO lock-up expiration | S-1, 8-K |
| Insider Buy/Sell | Named executive officer or director purchases or sells company shares | Form 4, Form 3 |
| Institutional New Position/Exit/Increase | Institutional investor initiates, exits, or materially increases a position in the company | 13F, SC 13G/D |
| Legal Action | New lawsuit filed against or by the company, or notice of government investigation | 8-K (8.01) |
| Litigation/Settlement | Legal settlement reached, case dismissed, or judgment issued | 8-K (8.01) |
| Loans/Revolvers | New credit facility entered, revolving credit line amended, or existing debt refinanced | 8-K (1.01) |
| Mergers and Acquisitions | Merger agreement, acquisition announcement, or binding letter of intent for a strategic combination | 8-K (1.01) |
| Mining and Exploration | Mineral resource discovery, exploration update, or reserve estimate revision | 8-K (7.01) |
| Minority Stakes Deals | Partial equity stake acquisition in or by the company, below full acquisition threshold | 8-K (1.01) |
| Name Change | Company legally changes its name or ticker symbol on a stock exchange | 8-K (5.03) |
| New Projects/Ventures | Major new business initiative, product launch, joint venture, or strategic partnership announced | 8-K (8.01) |
| Operations Update | Significant operational development such as a plant closure, production change, or supply chain event | 8-K (7.01) |
| Property Transaction | Real estate acquisition, disposal, sale-leaseback, or major lease signing | 8-K (1.01) |
| Regulatory Action | Action taken by a government agency or regulator — fine, consent order, investigation, or sanction | 8-K (8.01) |
| Restructuring | Formal restructuring plan announced including layoffs, business unit closures, or organizational changes | 8-K (2.05) |
| Shareholder Activism | Activist investor files a position, issues a public letter, or nominates board candidates | SC 13D |
| Staffing/Adds/Cuts | Significant workforce hiring program or reduction-in-force (RIF) announcement | 8-K (2.05) |
| Stock Buybacks | Share repurchase program announced, expanded, or completed | 8-K (8.01) |
| Trading Update | Trading halt, suspension, resumption, or exchange circuit-breaker event affecting the company’s shares | 8-K (3.01, 8.01) |